Background
Currently, direct-acting antivirals for SARS-CoV-2, such as remdesivir, molnupiravir, and nirmatrelvir, are widely used in clinical settings. These agents reduce viral load and mitigate disease severity and mortality. However, drug-resistant variants continue to emerge, highlighting the need for novel small-molecule antivirals that can be co-administered with existing therapies.
Methods
We synthesized more than 400 novel quinazoline derivatives and evaluated their antiviral activity against SARS-CoV-2 using VeroE6/TMPRSS2 cells and HEK293T/ACE2 cells. In vitro virological assays were conducted to assess antiviral efficacy. Biochemical assays using cell-free RNA synthesis reactions were performed to determine inhibitory effects on SARS-CoV-2 RNA-dependent RNA polymerase (RdRp). Molecular docking simulations were used to evaluate physicochemical interactions between the compounds and RdRp. Selected compounds were further tested in a BALB/c mouse infection model to assess in vivo antiviral efficacy.
Results
Several quinazoline derivatives demonstrated potent antiviral activity against SARS-CoV-2, with EC₅₀ values in the submicromolar range and CC₅₀ values >100 μM. These compounds retained efficacy against multiple variants, including Omicron. Biochemical assays revealed dose-dependent inhibition of RdRp activity. Docking simulations suggested strong binding affinity to the active site of RdRp. In vivo studies showed that one compound significantly reduced viral RNA levels in the lung tissues of infected BALB/c mice.
Conclusions
We identified a new class of selective and potent quinazoline derivatives that inhibit SARS-CoV-2 RdRp and are effective against various viral variants. Unlike nucleoside analogs, these compounds represent a distinct chemical class and may retain efficacy against drug-resistant strains. Their low molecular weight and short synthetic routes make them promising candidates for combination therapy with existing antivirals. These features also support their potential for affordable and globally accessible COVID-19 treatment.